Combination of Remdesivir, Corticosteroid, and Convalescent Plasma for Severe COVID-19 in Periviable Pregnancy. Issue 6 (November 2020)

• Record Type: Journal Article
• Authors: Lam, Helena; Lacasse, Alexandre
• Is Part Of: Infectious diseases in clinical practice. Volume 28:Issue 6(2020:Nov.)
• Publication Date: 2020-11
• Subjects: COVID-19 -- SARS-CoV-2 -- periviable pregnancy -- pregnancy -- remdesivir -- convalescent plasma therapy -- combination therapy -- corticosteroids -- COVID-19 management -- severe COVID-19 -- COVID-19 in pregnancy; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Periodicals; Electronic journals; 616.9
• DOI: 10.1097/IPC.0000000000000925
• Languages: English
• ISSNs: 1056-9103

Abstract

Abstract : Abstract: Infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may lead to a disease spectrum named COVID-19, including a severe form of pneumonia characterized by an intense inflammatory response similar to acute respiratory distress syndrome. Current management guidelines in pregnancy have been limited. In the setting of severe COVID-19 in pregnancy, including in the periviability period, combination multitargeted therapy should be strongly considered. We report a case of severe COVID-19 pneumonia in a periviable pregnancy treated with concurrent combination of remdesivir, corticosteroids, and convalescent plasma therapy, leading to rapid maternal pulmonary improvement.